CELZ Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.…
Industry Peers
BiotechnologyKey Statistics
About Creative Medical Technology Holdings (NASDAQ: CELZ)
›
Creative Medical Technology Holdings (NASDAQ: CELZ) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 0.5281 USD on 13 November 2026, down 82.3% over 52 weeks. Its 52-week range is 0.5281 USD to 4.720 USD, and it trades at the bottom of that range.
Its market capitalisation is 4.01M USD.
Creative Medical Technology Holdings reports return on equity of -79.8%.
It holds more cash than debt, a net cash position of 8.82M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.